Ocular Therapeutix™ to Present at the 2018 Cantor Global Healthcare Conference
September 26 2018 - 8:00AM
Business Wire
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that Antony Mattessich,
President and Chief Executive Officer of Ocular Therapeutix, will
present at the 2018 Cantor Global Healthcare Conference on
Wednesday, October 3, 2018 at 11:30 AM ET at the Intercontinental
Barclay Hotel in New York, NY.
In addition to the presentation, the management team will host
investor meetings at the conference. Investors attending the
conference who are interested in meeting with Ocular Therapeutix
management should contact their Cantor representative.
A live webcast of the presentation can be accessed by visiting
the Investors section of the Company’s website
at investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused
on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary bioresorbable hydrogel-based formulation
technology. Ocular Therapeutix’s lead product candidate, DEXTENZA®
(dexamethasone insert), has completed Phase 3 clinical development
for the treatment of ocular pain and inflammation following
ophthalmic surgery. The New Drug Application (NDA) for DEXTENZA has
a target action date under the FDA Prescription Drug User Fee Act,
or PDUFA, of December 28, 2018. OTX-TP (travoprost insert) is an
intracanalicular insert in Phase 3 clinical development for the
reduction of intraocular pressure in patients with primary
open-angle glaucoma and ocular hypertension. The Company’s earlier
stage assets include OTX-TIC, an extended-delivery travoprost
intracameral implant for the reduction of intraocular pressure in
patients with glaucoma and ocular hypertension, as well as
sustained release intravitreal implants for the treatment of
retinal diseases. These intravitreal implants include the
development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in
collaboration with Regeneron, OTX-IVT, an extended-delivery
protein-based anti-vascular endothelial growth factor (VEGF) trap.
Ocular Therapeutix's first product, ReSure® Sealant, is
FDA-approved to seal corneal incisions following cataract
surgery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180926005061/en/
InvestorsOcular TherapeutixDonald NotmanChief Financial
Officerdnotman@ocutx.comorWestwicke PartnersChris Brinzey,
339-970-2843chris.brinzey@westwicke.comorMediaOcular
TherapeutixScott CorningSenior Vice President,
Commercialscorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Sep 2023 to Sep 2024